Zim Laboratories Ltd

Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock.

Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges.

Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance.

Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day.

Zim Laboratories Ltd is experiencing increased buying activity, showing a slight gain today while the Sensex declines. Despite this, the stock has faced recent losses and significant declines over the past year, remaining below key moving averages, indicating ongoing challenges in its market position.

Zim Laboratories Ltd is experiencing significant selling pressure, continuing a trend of consecutive losses. The stock has underperformed compared to the Sensex over various time frames, with notable declines over the past year and three years. It is also trading below multiple moving averages, indicating ongoing challenges.

Zim Laboratories Ltd is experiencing notable buying activity, with a modest gain today and a slight increase over the past week. However, the stock has faced challenges in the longer term, showing declines over the past month and three months. Its current price is approaching a critical support level.

Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges for the microcap pharmaceutical company. The stock has consistently underperformed its sector, with significant declines in net sales and a low return on capital employed. The company has reported negative results for five consecutive quarters.

Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company has seen a significant decline in stock price over the past year, with notable decreases in net sales and profit after tax, indicating persistent market weakness.

Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges in its financial health. The company has underperformed its sector and is trading below key moving averages. Over the past year, it has seen a significant decline in net sales and negative results for five consecutive quarters.

Zim Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has consistently underperformed its sector and has faced a substantial decline over the past year. Financial metrics indicate ongoing challenges, including declining net sales and profitability issues.

Zim Laboratories Ltd is experiencing notable selling pressure, marked by consecutive losses and a significant decline over the past three months. The stock is trading near its 52-week low and remains below key moving averages, reflecting a challenging environment influenced by both market dynamics and company-specific factors.

Zim Laboratories has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has reported negative results for five consecutive quarters, with a notable drop in net sales and a decrease in return on capital employed, highlighting ongoing financial challenges.